leisure time -WSS

leisure time

author：comprehensive 2025-09-03 07:52:22 - browse：1

BiTE Bridge — Illustration of a BiTE, Amgen's bispecific antibodies Amgen

In cancer immunotherapy these days, technology is advancing so fast that 2017’s buzzy new treatment may soon be passe: Only 18 months after approval of the first CAR-T, pharmaceutical companies and biotechs are already talking about next-generation cancer therapy.

Called bispecific antibodies, they’re being developed by some two dozen companies large and small, with a version cleverly branded as BiTEs already constituting 60 percent of Amgen’s oncology pipeline. The appeal: Bispecifics make the immune system kill tumor cells like first-gen immunotherapy, but, unlike the weeks it takes to laboriously manufacture CAR-Ts, they can start being infused almost as quickly as an oncologist can write a prescription.

“We’re very bullish” on BiTEs, said Dr. David Reese, head of R&D at Amgen, which has the only cancer-targeting bispecific approved for clinical use in the U.S. and 14 more in development, including for multiple myeloma, small cell lung cancer, glioblastoma, and other solid tumors. “We can generate a BiTE against any tumor antigen we want to go after.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： First transplant of an entire human eye performed

Wikipedia

WSS

Carbon Health diabetes program, a test of data

First transplant of an entire human eye performed

UnitedHealth sued over use of algorithm in Medicare Advantage plans

New Alzheimer's drugs heat up race for early detection blood tests

US economic growth accelerated in 2nd quarter, exceeding expectations and quieting recession fears

Medical school prerequisites are outdated

hotspot

leisure time

knowledge

Malaria cases in Florida and Texas: Here’s what you need to know

What health policies could hitch a ride on a spending bill?

Apple is now the first public company to be valued at $3 trillion

New Alzheimer's drugs heat up race for early detection blood tests

Apple is now the first public company to be valued at $3 trillion

Former reverend arrested for allegedly killing 8

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

A new crop of companies is reshaping the health data economy

Novavax promises a turnaround & Lilly roils the obesity market

UHS says company favors patients whose insurance pays more

focus

Today's health inequities arise from racist U.S. history, say experts

STAT Report: Patient voices and perspectives

Medicare’s new pay boost for primary care is angering specialists

First transplant of an entire human eye performed

New lawsuit accuses health insurer Cigna of denying claims in bulk

Medicare’s new pay boost for primary care is angering specialists

explore

Wikipedia

leisure time

entertainment